Decitabine for acute myeloid leukemia

References

• Menzin J, Boulanger L, Karsten V et al. Effects of initial treatment on survival among elderly AML patients: findings from the SEER-medicare database. ASH Annu. Meet. Abstracts108, 1973 (2006).
   Google Scholar
• Lang K, Earle CC, Foster T, Dixon D, Van Gool R, Menzin J. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging22(11), 943–955 (2005).
   PubMed Web of Science ®Google Scholar
• Ditschkowski M, Elmaagacli AH, Trenschel R et al. Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients. Clin. Transplant.20, 127–131 (2005).
   Google Scholar
• Appelbaum FR, Gundacker H, Head DR et al. Age and acute myeloid leukemia. Blood107, 3481–3485 (2006).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi S, O’Brien S et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood116, 4422–4429 (2010).
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer109, 1114–1124 (2007).
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N. Engl. J. Med.358, 1148–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Mund C, Brueckner B, Lyko F. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics1, 7–13 (2006).
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood100, 2292–2302 (2002).
   PubMed Web of Science ®Google Scholar
• de Lima M, Giralt S, Thall PF et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer116, 5420–5431 (2010).
   PubMed Web of Science ®Google Scholar
• Baer MR, Gojo I. Novel agents for the treatment of acute myeloid leukemia in the older patient. J. Natl Compr. Canc. Netw.9, 331–335 (2011).
   Google Scholar
• Taksin AL, Legrand O, Raffoux E et al. High efficacy and safety profile of fractionated doses of Myelotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia21, 66–71 (2007).
   PubMed Web of Science ®Google Scholar
• Lavelle D, Chin J, Vaitkus K et al. Oral decitabine reactivates expression of the methylated γ-globin gene in Papio anubis. Am. J. Hematol.82, 981–985 (2007).
   PubMed Web of Science ®Google Scholar
• Pliml J, Sorm F. Synthesis of 2´-deoxy-D-ribofuranosyl-5-azacytosine. Coll. Czeck. Chem. Commun.29, 2576–2577 (1964).
   Web of Science ®Google Scholar
• Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer123, 8–13 (2008).
   PubMed Web of Science ®Google Scholar
• Sorm F, Vesely J. Effect of 5-aza-2´-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma15, 339–343 (1968).
   PubMed Web of Science ®Google Scholar
• Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP. 5-Aza-2´-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood64, 922–929 (1984).
   PubMed Web of Science ®Google Scholar
• Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin. Drug Metab. Toxicol.7(5), 661–672 (2011).
   PubMed Web of Science ®Google Scholar
• Van Groeningen C, Leyva A, O’Brien A et al. Phase 1 and pharmacokinetic study of 5-aza-2´deoxycytidine (NSC 1277716) in cancer patients. Cancer Res.46, 4831–4836 (1986).
   PubMed Web of Science ®Google Scholar
• Cashen AF, Shah AK, Todt L, Fisher N, DiPerso J. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother. Pharmacol.61, 759–766 (2008).
   PubMed Web of Science ®Google Scholar
• Daskalakis M, Blagitko-Dorfs N, Hackanson B. Decitabine. Recent Results Cancer Res.184, 131–157 (2010).
   PubMedGoogle Scholar
• Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2´-deoxycytidine in patients with acute leukemia. Pharmacol. Ther.30, 277–286 (1985).
   PubMed Web of Science ®Google Scholar
• Petti MC, Mandelli F, Zagonel V et al. Pilot study of 5-aza-2´-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia7, 36–41 (1993).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase 3 randomized study. Cancer106, 1794–1803 (2006).
   PubMed Web of Science ®Google Scholar
• Lübbert M, Suciu S, Baila L et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized Phase 3 study of the European organization for research and treatment of cancer leukemia group and the German MDS study group. J. Clin. Oncol.29, 1–11 (2011).
   Google Scholar
• Cashen AF, Schiller GJ, O’Donnell MR, DiPersio JF. Multicenter Phase 2 study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J. Clin. Oncol.28, 556–561 (2009).
   PubMed Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovic RB et al. Clinical response and miR-29b predictive significance [sic] in older patients treated with a 10-day schedule of decitabine. Proc. Natl Acad. Sci.107, 7473–7478 (2010).
   PubMed Web of Science ®Google Scholar
• Ravandi F, Issa JP, Garcia-Manero G et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer115, 5746–5751 (2009).
   PubMed Web of Science ®Google Scholar
• Thomas XG, Dmoszynska A, Wierbowska A et al. Results from a randomized Phase 3 trial of decitabine versus supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed AML. J. Clin. Oncol.29, 420s (2011).
   Google Scholar
• Blum W, Klisovic RB, Hackanson B et al. Phase 1 study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J. Clin. Oncol.25, 3884–3891 (2007).
   PubMed Web of Science ®Google Scholar
• Kirshbaum M, Gojo I, Goldber SL et al. Vorinostat in combination with decitabine for the treatment of relapsed or newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): a Phase 1 dose–escalation study. Blood114, 824 (2009).
   Google Scholar
• Ravandi F. Phase 1/2 study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia. J. Clin. Oncol.29, 440s (2011).
   Google Scholar
• Chowdhury S, Seropian S, Marks P. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. Am. J. Hematol.84, 599–600 (2009).
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood114, 237–251 (2009).
   Google Scholar